Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin

Thrombosis and Haemostasis

Volumn 91, Issue 1, 2004, Pages 87-94

  Gage, Brian F ^a   Eby, Charles ^a   Milligan, Paul E ^a   Banet, Gerald A ^a   Duncan, Jill R ^a   McLeod, Howard L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Cytochrome P 450 genetics; Genetic polymorphism; Pharmacogenetics; Warfarin administration dosage

Indexed keywords

ALLOPURINOL; AMIODARONE; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIINFLAMMATORY AGENT; CARBAMAZEPINE; CARINDACILLIN; CEFADROXIL; CEFALEXIN; CEFAZOLIN; CIMETIDINE; CLARITHROMYCIN; CLOFIBRATE; COTRIMOXAZOLE; CREATININE; CYTOCHROME P450 2C9; DALTEPARIN; DEXTROPROPOXYPHENE; ENOXAPARIN; ERYTHROMYCIN; FLUCONAZOLE; FRAGMON; HEPARIN; HEXACYCLINE; ISONIAZID; LEVOTHYROXINE SODIUM; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OFLOXACIN; OMEPRAZOLE; PHENYTOIN; PROPAFENONE; PURINOL; QUINIDINE; QUINIDINE GLUCONATE; QUINIDINE SULFATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SIMVASTATIN; SPARFLOXACIN; SULFINPYRAZONE; TAMOXIFEN; TAMOXIFEN CITRATE; THIAMAZOLE; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN; ZAFIRLUKAST;

ADULT; AFRICAN AMERICAN; AGE; AGED; ALGORITHM; ALLELE; ANAMNESIS; ARTICLE; BLOOD SAMPLING; BODY SURFACE; CARDIOMYOPATHY; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DEMOGRAPHY; DIET; DOSE CALCULATION; DRUG OVERDOSE; FACTORIAL ANALYSIS; FEMALE; FOOD DRUG INTERACTION; GENETIC MODEL; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL STANDARD UNIT; LABORATORY TEST; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RACE DIFFERENCE; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; THROMBOSIS;

EID: 1542782670     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/th03-06-0379     Document Type: Article

References (66)

1. Evans WE, McLeod HL. Pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003; 348: 538-49.
2. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
3. Phillips K, Veenstra D, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review. JAMA 2001; 286: 2270-79.
4. Aithal GP, Day CP, Kesteven PJL, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
5. Takahashi H, Kashima T, Nomizo Y, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-28.
6. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5: 389-92.
7. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996; 6: 429-39.
8. Yamazaki H, Inoue K, Shimada T. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 1998; 28: 103-15.
9. Rogers JF, Nafziger AN, Bertino J, et al. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. The American Journal of Medicine 2002; 113: 746-50.
10. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-8.
11. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 2000; 96: 1816-9.
12. Loebstein R, Yonath H, Peleg D, et al. Inter-individual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther 2001; 70: 159-64.
13. Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
14. Imai J, Ieiri I, Mamiya K, et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: Genetic analysis of the CYP2C9 locus. Pharmacogenetics 2000; 10: 85-9.
15. Dickmann LJ, Rettie AE, Kneller MB, et al. Identification and Functional Characterization of a New CYP2C9 Variant (CYP2C9*5) Expressed among African Americans. Mol Pharmacol 2001; 60: 382-7.
16. Leung AY, Chow HC, Kwong YL, et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001; 98: 2584-7.
17. White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med 1999; 107: 414-24.
18. Landefeld SC, Beyth R. Anticoagulant-related bleeding: Clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-28.
19. Fihn SD, McDonnell M, Martin D, et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Intern Med 1993; 118: 511-20.
20. Douketis JD, Foster GA, Crowther MA, et al. Clinical Risk Factors and Timing of Recurrent Venous Thromboembolism During the Initial 3 Months of Anticoagulant Therapy. Arch Intern Med 2000; 160: 3431-6.
21. Beyth RJ, Quinn L, Landefeld CS. Multi-component Intervention to Prevent Major Bleeding Complications in Older Patients Receiving Warfarin. A Randomized, Controlled Trial. Ann Intern Med 2000; 133: 687-95
22. Gurwitz J, Avorn J, Ross-Degnan D, et al. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992; 116: 901-4.
23. Routledge P, Chapman P, Davies D, et al. Factors affecting warfarin requirements: A prospective population study. Eur J Clin Pharmacol 1979; 15: 319-22.
24. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002; 36: 1512-7.
25. Blann A, Hewitt J, Siddiqui F, et al. Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0. Br J Haematol 1999; 107: 207-9.
26. Garten S, Wosilait WD. Comparative study of the binding of coumarin anticoagulants and serum albumins. Biochem Pharmacol 1971; 20: 1661-8.
27. Mungall DR, Ludden TM, Marshall J, et al. Population kinetics of racemic warfarin. Journal of Pharmacokinetics and Biopharmaceutics 1985; 13: 213-27.
28. James AH, Britt RP, Raskino CL, et al. Factors affecting the maintenance dose of warfarin. J Clin Pathol 1992; 45: 704-6.
29. Ristola P, Pyorala K. Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction. Acta Med Scand 1972; 192: 183-8.
30. Fergusson RJ, Eade OE, Logie AW, et al. A flexible loading dose schedule for warfarin therapy. Scott Med J 1987; 32: 169-71.
31. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000; 109: 481-8.
32. Shibata Y, Hashimoto H, Kurata C, et al. Influence of physical activity on warfarin therapy. Thromb Haemost 1998; 80: 203-4.
33. Lubetsky A, Dekel-Stern E, Chetrit A, et al. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost 1999; 81: 396-9.
34. Cushman M, Booth SL, Possidente CJ, et al. The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 2001; 112: 572-7.
35. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 1998; 281: 363-5.
36. Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome Res 2001; 11: 3-11.
37. Schechtman KB, Barzilai B, Rost K, et al. Measuring physical activity with a single question. Am J Public Health 1991; 81: 771-3.
38. DuBois D, DuBois E. Clinical Calorimetry; A formula to estimate the approximate surface area if height and weight be known. Arch Int Med 1916; 17: 863-71.
39. Chan K, Lo AC, Yeung JH, et al. The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol 1995; 47: 402-6.
40. Page RL, 2nd, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999; 19: 870-6.
41. Booth SL, Centurelli MA. Vitamin K: A practical guide to the dietary management of patients on warfarin. Nutr Rev 1999; 57: 288-96.
42. Raschke R, Reilly B, Guidry J, et al. Weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med 1993; 119: 874-81.
43. Efron B, Tibshirani R. An Introduction to the Bootstrap. 57 vol. New York: Chapman & Hall;
44. Mooney CZ, Duval RD. Bootstrapping: A Nonparametric Approach to Statistical Inference. Newbury Park, CA: Sage Publications, Inc.; 1993.
45. Goldford M, Backus J, Triscott M. Solid phase genotyping of the warfarin metabolizing enzyme CYP2C9 with DNA probes [abstract]. Thromb Haemost 2001; July Supp: 674.
46. Palareti G, Manotti C, A DA, et al. Thrombotic events during oral anticoagulant treatment: Results of the inception-cohort, prospective, collaborative ISCOAT study: ISCOAT study group (Italian Study on Complications of Oral Anticoagulant Therapy). Thromb Haemost 1997; 78: 1438-43.
47. AGS Clinical Practice Committee. The use of oral anticoagulants (warfarin) in older people. AGS Clinical Practice Committee. J Am Geriatr Soc 1996; 44: 1112-3.
48. Ezekowitz MD, James KE, Radford MJ, et al. Initiating and maintaining patients on warfarin anticoagulation: The importance of monitoring. J Cardiovasc Pharmacol Ther 1999; 4: 3-8.
49. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001; 119: 22S-38S.
50. Horton JD, Bushwick BM. Warfarin therapy: Evolving strategies in anticoagulation. Am Fam Physician 1999; 59: 635-46.
51. Gunnarsson PS, Sawyer WT, Montague D, et al. Appropriate use of heparin. Empiric vs nomogram-based dosing. Arch Intern Med 1995; 155: 526-32.
52. Wynne H, Cope L, Kelly P, et al. The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 1995; 40: 203-7.
53. Shepherd AM, Hewick DS, Moreland TA, et al. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 1977; 4: 315-20.
54. Fennerty A, Dolben J, Thomas P, et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J (Clin Res Ed) 1984; 288: 1268-70.
55. Gedge J, Orme S, Hampton KK, et al. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 2000; 29: 31-4.
56. Gladman JR, Dolan G. Effect of age upon the induction and maintenance of anticoagulation with warfarin. Postgrad Med J 1995; 71: 153-5.
57. Roberts GW, Druskeit T, Jorgensen LE et al. Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust N Z J Med 1999; 29: 731-6.
58. Rettie AE, Tai G, Veenstra DL, et al. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood 2003; 101: 2896-7.
59. Zarza J, Hermida J, Montes R, et al. Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population. Blood 2002; 100: 734.
60. Sanoski CA, Bauman JL. Clinical observations with the Amiodarone/Warfarin Interaction: Dosing relationships with long-term therapy. Chest 2002; 121: 19-23.
61. Harrell FE Jr, Lee KL, Mark DB. Multi-variable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-87.
62. Ageno W, Turpie AG. Exaggerated initial response to warfarin following heart valve replacement. Am J Cardiol 1999; 84: 905-8.
63. Kidd RS, Curry TB, Gallagher S, et al. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 803-8.
64. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133-6.
65. Hylek EM, Singer D. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
66. Hiratsuka M, Agatsuma Y, Mizugaki M. Rapid detection of CYP2C9*3 alleles by real-time fluorescence PCR based on SYBR Green. Mol Genet Metab 1999; 68: 357-62.